Booster vaccines reduced the risk of COVID‑19–related hospitalisation and death, according to a new study of over 3 million ...

Booster vaccines reduced the risk of COVID‑19-related hospitalization and death, according to a new study of over 3 million adults who had the autumn 2022 vaccine in England. The research, led by the ...

The U.S. Food and Drug Administration announced recently that it will not review Moderna’s mRNA flu vaccine, despite late-stage trials showing it was safe and effective. The rejection has many in and ...

The Food and Drug Administration rejected Moderna's new flu shot. This raises questions about what it means for the future of vaccine development.

Studies show Depo-Provera users have much higher relative risk of developing meningiomas, although overall risk remains low ...

Studies show that women who use a contraceptive injection known as Depo-Provera could increase their risk of benign brain ...

Studies show that women who use a contraceptive injection known as Depo-Provera could increase their risk of benign brain tumours by as much as 500 per cent.

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's supplemental Biologics License Application (sBLA) for HYMPAVZI® ...

Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on new obesity drug data, and Merck laid out its post-Keytruda future.

Pfizer on Tuesday released trial data on a high-profile obesity drug from its recent $10 billion Metsera purchase that raises questions about its tolerability for patients, and shares of the U.S.

By Michael Erman and Mrinalika Roy Feb 3 (Reuters) - Pfizer on Tuesday released trial data on a high-profile obesity drug from its recent $10 billion Metsera purchase that raises questions about its ...

Pfizer targets 2028 for its first obesity drug approval Company plans to advance more than 20 obesity trials in 2026 RSV vaccine quarterly sales top expectations Feb 3 (Reuters) - Pfizer (PFE.N), ...